Stamford Pharmaceuticals   Report issue

For profit Phase 2
Founded: South Melbourne Australia (2003)

Organization Overview

First Clinical Trial
2015
NCT02550678
First Marketed Drug
2004
estradiol (progynon depot)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Ascend Biopharmaceuticals Ltd | ASCEND THERAPS US

Active Ingredients

Marketed Drugs (2)

alendronic acid (fosamax) (2012)

estradiol (progynon depot) (2004)

Drugs in Phase 2 Trials (2)

fluorouracil (efudex) (1 trial)

Gusacitinib (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Basal Cell Nevus Syndrome (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Basal Cell (Phase 2)

Nevus (Phase 2)

Nevus, Pigmented (Phase 2)

Skin Neoplasms (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2